Logo
Logo

About Voclosporin API

Product
  • Therapeutic CategoryNephrology

  • API Technology

    Synthetic

  • Dose Form

    Oral Solid/Capsules

  • Dr Reddy's Development Status

    Available (Commercial)

  • Available Regulatory Filing

    USDMF

Mechanism of Action

Voclosporin is an immunosuppressant drug that works by inhibiting the activity of an enzyme called calcineurin. Calcineurin is involved in the activation of T cells, which are a type of white blood cell that play a key role in the immune system.

In individuals with autoimmune diseases such as lupus nephritis, the immune system mistakenly attacks healthy tissues and organs, causing inflammation and damage. Voclosporin works by blocking calcineurin and therefore inhibiting the activation of T cells, which helps to reduce the inflammation and prevent tissue damage.

In addition to its immunosuppressive effects, voclosporin has also been shown to have antiproliferative and anti-inflammatory effects, which may contribute to its ability to improve outcomes in patients with lupus nephritis.

It is important to note that while voclosporin can be effective in controlling the symptoms of autoimmune diseases, it can also suppress the immune system, making patients more susceptible to infections. As with any medication, the benefits and risks of voclosporin should be carefully weighed by a healthcare provider before it is prescribed.

Indication

Voclosporin is indicated for the treatment of certain autoimmune diseases, specifically for the treatment of lupus nephritis. Lupus nephritis is a type of kidney disease that occurs in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease in which the body's immune system attacks its own tissues and organs.

Voclosporin is used in combination with another immunosuppressant, mycophenolate mofetil, to improve kidney function and reduce the risk of kidney failure in patients with lupus nephritis.

It is important to note that the safety and effectiveness of voclosporin may vary depending on individual circumstances and that patients should consult their healthcare provider to determine if voclosporin is appropriate for their treatment. Additionally, patients taking voclosporin may require monitoring for potential side effects and drug interactions.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Voclosporin API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Voclosporin API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

RFQ Form

Phone

FAQs

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.